Strs Ohio Sells 21,300 Shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)

Strs Ohio cut its holdings in shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) by 14.3% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 127,500 shares of the company’s stock after selling 21,300 shares during the period. Strs Ohio’s holdings in Amneal Pharmaceuticals were worth $773,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in AMRX. Ritholtz Wealth Management bought a new stake in Amneal Pharmaceuticals during the third quarter worth $343,000. SG Americas Securities LLC bought a new position in shares of Amneal Pharmaceuticals in the 3rd quarter valued at $221,000. Raymond James & Associates lifted its stake in shares of Amneal Pharmaceuticals by 12.4% in the 3rd quarter. Raymond James & Associates now owns 181,387 shares of the company’s stock valued at $765,000 after acquiring an additional 20,000 shares during the last quarter. Bank of New York Mellon Corp lifted its stake in shares of Amneal Pharmaceuticals by 9.6% in the 3rd quarter. Bank of New York Mellon Corp now owns 688,362 shares of the company’s stock valued at $2,905,000 after acquiring an additional 60,024 shares during the last quarter. Finally, Principal Financial Group Inc. lifted its stake in shares of Amneal Pharmaceuticals by 10.3% in the 3rd quarter. Principal Financial Group Inc. now owns 54,432 shares of the company’s stock valued at $230,000 after acquiring an additional 5,092 shares during the last quarter. 31.82% of the stock is currently owned by institutional investors.

Amneal Pharmaceuticals Stock Up 12.0 %

Shares of NASDAQ:AMRX opened at $6.05 on Thursday. The firm has a market cap of $1.86 billion, a P/E ratio of -19.52 and a beta of 1.33. The company has a quick ratio of 0.94, a current ratio of 1.63 and a debt-to-equity ratio of 121.31. Amneal Pharmaceuticals, Inc. has a 12-month low of $1.64 and a 12-month high of $6.46. The business has a fifty day simple moving average of $5.72 and a 200 day simple moving average of $5.17.

Amneal Pharmaceuticals (NASDAQ:AMRX) last issued its quarterly earnings results on Friday, March 1st. The company reported $0.12 earnings per share for the quarter, topping analysts’ consensus estimates of $0.05 by $0.07. Amneal Pharmaceuticals had a positive return on equity of 126.04% and a negative net margin of 3.51%. The firm had revenue of $616.98 million during the quarter, compared to the consensus estimate of $630.67 million. Analysts predict that Amneal Pharmaceuticals, Inc. will post 0.5 earnings per share for the current year.

Analysts Set New Price Targets

AMRX has been the subject of a number of research reports. Piper Sandler increased their price target on Amneal Pharmaceuticals from $6.00 to $8.00 and gave the company an “overweight” rating in a research note on Thursday, March 21st. The Goldman Sachs Group increased their price target on Amneal Pharmaceuticals from $5.50 to $6.25 and gave the company a “buy” rating in a research note on Monday, March 4th. StockNews.com lowered Amneal Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Monday, March 4th. Finally, Barclays raised their target price on Amneal Pharmaceuticals from $6.00 to $8.00 and gave the stock an “overweight” rating in a research report on Monday, January 29th. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average price target of $7.31.

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.